Dave Levitan

Tumor-infiltrating lymphocytes have significantly higher expression of PD-L1 in pregnancy-associated breast cancer compared to nulliparous breast cancer patients. This may help predict response to therapy, among other outcomes.

Over the long term, local recurrence is more likely in young women with invasive breast cancer who undergo breast conserving surgery compared with those who undergo mastectomy, though survival is no different.

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy significantly increased response rates among women with BRCA1 or BRCA2 mutations and locally recurrent or metastatic breast cancer, according to a randomized phase II trial.

Circulating tumor DNA (ctDNA) measured by liquid biopsy was able to identify actionable mutations and provide a real-time molecular assessment of metastatic breast cancer, according to a new study.

In a potential step toward precision endocrine therapy, a new study found that certain single nucleotide polymorphisms within CSMD1 are associated with changes in estrogen levels in postmenopausal breast cancer patients.

The addition of everolimus to fulvestrant was associated with more than a doubling of progression-free survival in women with metastatic hormone receptor–positive, HER2-negative breast cancer who were resistant to aromatase inhibitor therapy.

Whole exome and transcriptome sequencing found that the genomic landscape of estrogen receptor-positive metastatic breast cancer differs from that of primary tumors.

A biosimilar yielded equivalent response rates to trastuzumab at 24 weeks in a study of women with HER2-positive metastatic breast cancer.

Long-term follow-up showed no reduction in prostate cancer mortality with yearly prostate-specific antigen testing.

In patients with HER2-positive breast cancer undergoing trastuzumab therapy, the use of an ACE inhibitor or beta-blocker could protect against cardiac toxicity.

A retrospective review showed that primary cytoreductive surgery was associated with longer survival than neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer.

A case study found that a patient with an inflammatory myofibroblastic tumor and a chromoplectic TPM3-ALK rearrangement that may be involved in tumorigenesis had a strong response to the ALK inhibitor ceritinib.

The use of radiotherapy was associated with an overall survival benefit in patients with prostate cancer and lymph node involvement who underwent radical prostatectomy and were also treated with androgen-deprivation therapy.

An updated prognostic tool incorporating gene alteration data could help guide clinical management of patients with non–small-cell lung cancer.

Expression of mesothelium vascular cell adhesion molecule-1 (VCAM-1) is associated with poorer overall and progression-free survival in patients with epithelial ovarian cancer, according to a retrospective analysis.

According to a long-term follow-up analysis of a phase I/II trial, bosutinib provides durable responses and a favorable toxicity profile in patients with chronic phase CML who are resistant/intolerant to other tyrosine kinase inhibitors.

Cabozantinib alone or in combination with erlotinib improved survival outcomes among patients with advanced EGFR wild-type non–small-cell lung cancer.

The use of a metronomic chemotherapy approach did not improve over standard chemotherapy in patients with high-grade, non-metastatic, operable osteosarcoma of the extremities.

Metastatic renal cell carcinoma (mRCC) patients who use non-aspirin NSAIDs have poorer overall survival than aspirin users and NSAID non-users, according to a new pooled retrospective analysis.

Patients with ALK-rearranged NSCLC treated with brigatinib showed promising response rates in both crizotinib-treated and crizotinib-naive patients.

Polymorphisms in the FCGR3A gene are correlated with degree of benefit from trastuzumab in women with ERBB2/HER2-positive breast cancer, according to a new analysis.

The use of surveillance did not affect survival among women with stage I malignant ovarian germ cell tumors, according to a new retrospective analysis.

Expression levels of CD62L and related immunologic markers are correlated with treatment responses and outcome in patients with CML, according to a new analysis. The markers could have prognostic value if validated in other cohorts.

The antibody-drug conjugate trastuzumab emtansine (T-DM1) showed non-inferior-but not superior-efficacy to trastuzumab plus a taxane in women with advanced HER2-positive breast cancer.

With a number of therapies now available for treatment of renal cell carcinoma, research is now ongoing to determine the best possible sequencing and potential combinations of those therapies.

The use of proton pump inhibitors does not appear to impact the efficacy of oral VEGF tyrosine kinase inhibitors in metastatic renal cell carcinoma, according to a new study.

Despite evolution of treatments and substantial improvements in survival, the self-reported health status among adult survivors of childhood cancers has not improved over 3 decades.

The use of immune checkpoint inhibitors as adjuvant or neoadjuvant therapy in kidney cancer could offer important new treatment options. Questions remain, though, on the timing and sequence of therapy.

Specific tumor genotypes could represent distinct subtypes of clear cell renal cell carcinoma, according to a new analysis of the RECORD-3 trial. Genotyping could potentially help guide treatment decisions if the results can be validated.

A small study found that patients with metastatic renal cell carcinoma (mRCC) who discontinue nivolumab due to immune-related adverse events can continue to derive benefit even after cessation of therapy.